ReviewCell2024
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.
Review in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 356 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
356 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Liquid biopsy proteomics in ophthalmology : A clinical and scientific perspective].Die Ophthalmologie · 2026Pooled it
- The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Epigenetic silencingCancer biology & therapy · 2026Article
- Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.Drug delivery · 2026Review
- Serum HE4 and polymorphisms in MMP9 and MMP13 associated with survival outcome in patients with endometrial carcinoma: a retrospective cohort study and nomogram development.Future science OA · 2026Article
- Genomic instability, postoperative recurrence and therapeutic vulnerabilities in resectable non‑small cell lung cancer (Review).Oncology reports · 2026Review
- Rethinking biomarkers in psychiatry: from etiological uncertainty to actionable prediction.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2026Article
- AMCP Market Insights: Managed care approaches toJournal of managed care & specialty pharmacy · 2026Article
- LncRNA MIR22HG and miR-10a-5p: Pioneering serum biomarkers for pancreatic cancer diagnosis and progression assessment.Non-coding RNA research · 2026Article
- Utilizing Machine Learning to Identify Multimodal Signatures for Patients Who Would Benefit from the Addition of Tremelimumab to Durvalumab and Chemotherapy (TRIDENT).Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Observational
- A biomarker-driven approach to targeting polyamine depletion in triple negative breast cancer.Biomarker research · 2026Article
- From virtual screening to cell-based assays: structure-guided identification of EGFR-targeting perimidine derivatives with anticancer activity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Special Issue "Molecular Biomarkers in Cancers: Advances and Challenges".International journal of molecular sciences · 2026Article
- Ensemble learning of pathology foundation models for precision oncology.Cancer cell · 2026Article
- MACC1 Hyperactivates Receptor Tyrosine Kinase Signaling Through Phosphorylation-Dependent Adaptor Activity in Colorectal Cancer Cells.Biomolecules · 2026Article
- Integrative pan-cancer analysis identifies CCHCR1 as a prognostic biomarker and therapeutic target driving EMT in hepatocellular carcinoma via PI3K/AKT activation.Genes & diseases · 2026Article
- BOMIFA: biologically informed multi-omics integration with graph contrastive learning for cancer prognosis in women.Briefings in bioinformatics · 2026Article
- Development of clinical-radiological prediction models to prioritizeJournal of thoracic disease · 2026Article
- Prognostic impact of CEACAM5 in nonsquamous non-small cell lung cancer: a critical reappraisal driven by cut-off optimization.Translational lung cancer research · 2026Article
- UDP-Glucose-6-Dehydrogenase Mediated O-GlcNAcylation of Tight Junction Protein 1 Suppresses Metastasis in Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
296 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.